AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05654909 — intervention group
Intervention type: PROCEDURE
Intervention: Prehospital assessment unit
Description: The prehospital assessment unit was developed to provide a paramedic responding by car to 1-1-2 calls in the area of Region Zealand. Further details are mentioned in the description.
Study NCT05895253 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: vibrotactile ground-contact feedback
Description: Suralis®, Saphenus Medical Technology (Baden, Lower Austria, Austria)
Study NCT04810819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 40 MG Injection;Dihydroxypropyltheophylline;
Description: Before anesthesia induction, 80 mg methylprednisolone and 100 ml saline were given intravenously, and 0.25 g dihydroxypropyltheophylline and 100 ml normal saline were given intravenously.
Study NCT04810819 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04523649 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote atrial fibrillation screening with handheld single lead ECG recorder
Description: Patients in this group will be given a handheld single lead ECG recorder (Comfit Healthcare Devices Limited, Hong Kong SAR, China) and a patient-facing smartphone application specially designed for the study, and they will be requested to record daily ECG and certain vital measurement.
Study NCT06214845 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Red blood cell EXchange (REX)
Description: A single automated REX will be performed, as soon as possible after randomization.
Study NCT06214845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell EXchange (REX)
Description: A single automated REX will be performed, as soon as possible after randomization.
Study NCT04666259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001
Description: Asciminib will be supplied as 20 mg or 40 mg strength tablets will be administered orally in accordance with the assigned cohort.
Study NCT05094674 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Sample analysis
Description: The participant's breath sample is taken by blowing preferably three times into a disposable tube. Thereafter, the tube is sealed, sterilized, and scanned by the BioSafety Station for analysis. This will take place once during the study.
Study NCT05766917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer education group
Description: Patients in this group will receive the routine hospital care, in addition to the proposed peer education by trained peer
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan
Study NCT06200103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo active monitoring
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo SPECT/CT or PET/CT
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo SPECT/CT or PET/CT
Study NCT06200103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT06200103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68 Gozetotide
Description: Given IV
Study NCT06200103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV
Study NCT06200103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Vipivotide Tetraxetan
Description: Given IV
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06200103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06200103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT06200103 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study NCT04262596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Consulting System
Description: Potential participants use the Interactive Consulting System on a mobile application with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
Study NCT04262596 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A traditional patient decision aid brochure
Description: Potential participants receive a traditional patient decision aid brochure with information about cataract surgery choice, and outcome data will be gathered using standardized questions in a structured interview after 2 weeks.
Study NCT06452719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 10 mg orally daily for three consecutive days
Study NCT06452719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Misoprostol 800 mcg vaginally within 24 hours of final letrozole dose
Study NCT05012722 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sphygmocor CVMS (Atocr Medical, Sydney Australia) PWV measurement
Description: All patients included in this study will have a pulse wave velocity measurement measured using SphygmoCor cardiovascular management system (CVMS) (Atocr Medical, Sydney Australia) which is a tonometry-based device used to noninvasively obtain vital cardiovascular data.
Study NCT05263232 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Natural or artificial office light exposure
Description: Over 4.5 days, participants will stay at our research facilities under different light conditions. Over these days different measurements will take place, including 24h continuous glucose monitoring, 24h blood and saliva sampling, 24h blood pressure and heart rate assessments, 24h core and skin temperature assessments, 24h energy expenditure and whole-body substrate metabolism, and a skeletal muscle biopsy and a mixed meal tolerance test with indirect calorimetry will be performed on the respectively last test day.
Study NCT05085613 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
Study NCT05085613 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Corrective message framing and humor
Description: The main content of the messages will be the same. Experimental conditions (arms 2-4) will additionally include consequent framing as a result of getting vaccinated (e.g. economic recovery for arm 2 and freedom for arm 3) and humor for arm 4. Participants will be randomized to view one of the four messages.
Study NCT05349110 — intervention group
Intervention type: DEVICE
Intervention: Computer-aided diagnosis (CADx) systems
Description: * AI4CRP (artificial intelligence for colorectal polyps), a CNN based computer-aided diagnosis system for diagnosis of colorectal polyps (COMET-OPTICAL research group);~* CAD EYE, a computer-aided diagnosis system for diagnosis of colorectal polyps (Fujifilm® Corporation, Tokyo, Japan).
Study NCT06527183 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin punch biopsy to demonstrate small fiber neuropathy
Description: Skin punch biopsy to assess intrapidermal nerve fiber density
Study NCT04711525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental Group: Interactive Malaysian Childhood Healthy Lifestyle Program (i-MaCHeL)
Description: The preschool children in the experimental group will be received the i-MaCHeL program delivers through interactive classroom instruction, and their parents will have access to the i-MaCHeL Web-based program.
Study NCT04716699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and tumor samples
Study NCT04716699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Given IV
Study NCT04716699 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection per standard of care
Study NCT04711525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group: Standard health education
Description: The children in the control group will be continued with standard health education only in the preschool setting, and their parents will be received general Web-based health newsletters.
Study NCT05939661 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Neoadjuvant radiation therapy : 5Gyx5
Study NCT05939661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: CAPOX (Oxaliplatin 130mg/m2, Capecitabine2000mg/m2/day, d1-14, 3week)x6cycles
Study NCT05939661 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Operation: Total methorectum excision wiht radical lymph node dissection
Study NCT04253548 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iPeer2Peer Support Mentorship Program
Description: iPeer2Peer is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.
Study NCT06544551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfacon-2
Description: Peginterferon Alfacon-2 injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
Study NCT06544551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon Alfacon-2 placebo
Description: Peginterferon Alfacon-2 placebo injection will be weekly subcutaneous injected for 48 weeks. Tenofovir alafenamide Fumarate Tablets(TAF) will be take orally for at least 48 weeks, not more than 72 weeks. Peg-interferon Alfacon-2 and TAF will discontinue when HBsAg levels is less than 0.05 IU/mL and HBV DNA is below 10 IU/mL during 48-72 weeks.
Study NCT04857307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alprazolam
Description: * Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points.
Study NCT04191239 — intervention group
Intervention type: DEVICE
Intervention: GE ventilator with two different modes
Description: GE ventilator with two different modes
Study NCT05402449 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same Additives to Probiotic group but replace probiotics with Corn starch and Maltodextrin.
Study NCT05402449 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Multi-strain probiotic supplement includes Lactobacillus reuteri GMNL-263 (heat-killed) and GMNL-89 (alive) and Lactobacillus rhamnosus GMNL-74 ( alive).
Study NCT04584125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% with UV light
Description: A wavelength of 365 nm ultraviolet A light will be used to direct 5.4 J/cm2 using a beam diameter of 9.5mm to treat the de-epithelialized corneal surface of a donor cornea for 30 minutes. Every 2 minutes, the UV light will be used while another drop of riboflavin is applied on top of the donor cornea.
Study NCT04584125 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Riboflavin 5'-phosphate in 20% dextran ophthalmic solution) 0.146% without UV light
Description: The corneal tissue for the control arm will be treated the same as the crosslinked tissue except that it will not be exposed to ultraviolet light. The donor cornea will be placed on an artificial anterior chamber maintainer and the epithelium will be removed mechanically. Riboflavin solution (0.1% riboflavin and 20% dextran supplied in a sterile, single-dose container) will be applied to the cornea every 2 minutes for 30 minutes.
Study NCT05182814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study NCT05391009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF exercise twice daily five days per week for 8 weeks. D1 and D2 flexion and extension pattern for upper limb. In D1 Flexion-adduction -external rotation d1, extension -abduction-internal rotation and in D2 flexion-abduction-external rotation, extension-adduction-internal rotation
Study NCT05391009 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: TRT
Description: The duration of a TRT session Will be 60 min. Each session started with warm-up exercises for 10 min followed by 50 min of TRT. Each task will be repeated approximately 10 to 20 times, for 1 to 5 sets, or alternatively for 2 to 5 min. A 2 min rest period after every 15 min of practice will be allowed. Before commencing the exercise session, tasks will be demonstrated to each patient using the non-affected UE.
Study NCT05182814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Juice Drink
Description: Testing product
Study NCT06238908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGGT003
Description: Single intravenous infusion of NGGT003 at low dose (4e11vg/kg), medium dose (1e12vg/kg) and high dose (2.5e12vg/kg)
Study NCT05435001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter ECG Monitoring
Description: Holter electrocardiogram monitoring will be carried out for 24 h simultaneously with the PSG monitoring using a 2- lead ambulatory electrocardiograph (Fysiologic; kind courtesy: MedTech Company, Amsterdam, Holland). We will calculate the time-domain, frequency-domain and non-linear indices by HRV. Several parameters describing the differences between RR intervals will be calculated: the square root of the mean of the sum of the squares of differences between adjacent normal RR intervals (r-MSSD), SD of NN intervals (SDNN), SD of the averages of NN intervals in all 5-minute segments of the recording (SDANN), and mean of the SD of all NN intervals for all consecutive 5-minute segments of the recording (SDNN index). All variables will be calculated for the 24-hour, daytime (2:00 to 9:00 PM), and nighttime (midnight to 7 AM) periods, and the differences between daytime and nighttime values (D\[D/N\]) will be computed.
Study NCT06465823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bumetanide
Description: Patients in the Bumetanide group will be treated for 3 months with a dose of 0.02 mg/kg twice a day, oral administration. It will be labeled (pre-printed and indistinguishable) with the randomization number and site number and will be delivered in separate blocks during the first, second and fourth appointment.~The patients will start the treatment with half of the full target dose during the first week:~* If the target dose is 0.5mg BID, only the morning dose will be administrated.~* If the target dose is 1.0 mg BID the dose will be 0.5 mg BID.~* If the target dose is 1.5mg BID, the morning dose will be 1.0 mg, the evening dose will be 0.5 mg.~* If the target dose is 2.0 mg BID the dose will be 1.0 mg BID The patient will continue with the full dose starting from Visit 2 after 1 week of dosing.
Study NCT06465823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the control (placebo) group will be given placebo for 3 months twice a day, oral administration. The Placebo tablets will be visually indistinguishable from Bumetanide and packaged as Bumetanide. The placebo will be labeled (pre-printed and indistinguishable) with the randomisation number and site number and will be delivered in separate blocks during the first, second and fourth visits.
Study NCT05152966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: Ablation using the FARAPULSE™ Cardiac Ablation System Plus
Study NCT05758610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETH-155008
Description: ETH-155008 is an orally bioavailable, potent Pim-3 and CDK4/6 dual kinase inhibitor.~Dosage form: 10mg, 20 mg and 40 mg, tablets. ETH-155008 tablets should be taken while fasting, either 1 hour before or 2 hours after a meal.
Study NCT06318988 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation using Closure fast
Description: Thermal ablation technique
Study NCT06318988 — intervention group
Intervention type: PROCEDURE
Intervention: Aethoxysclerol
Description: sclero-or foamsclerose
Study NCT06318988 — intervention group
Intervention type: DRUG
Intervention: Daflon
Description: Venoactive drugs
Study NCT06318988 — intervention group
Intervention type: DEVICE
Intervention: Compression stocking
Description: Compression
Study NCT05045079 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Inferior Vena Caval (IVC) Occlusion maneuver
Description: During standard of care right heart catheterization (RHC), a second catheter will be inserted next to the catheter that was placed for the RHC in the jugular vein or femoral vein to assess the degree of pericardial restraint from the severe tricuspid regurgitation that may increase left sided filling pressures.
Study NCT05601401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: RC48-ADC 2.0 mg/kg IV every 14 days
Study NCT06212700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Exercise
Description: Aerobic (HIIT) Endurance Respiratory Muscle Strength Education
Study NCT06212700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Exercise
Description: Aerobic Muscle Strength Walking Program Education
Study NCT06212700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative Nutrition
Description: Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
Study NCT06212700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Postoperative Nutrition
Description: Malnutrition screening Weight monitoring Symptom management Dietetic counselling Nutrition support
Study NCT06212700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Psychology
Description: CBT skills Skills training Emotional validation Behavioural activation Psycho-education
Study NCT06212700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Postoperative Psychology
Description: CBT skills Skills training Emotional validation Behavioural activation Psycho-education
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Nursing
Description: Comorbidities Managing pain Wound care Complications Surgical education ERAS
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Nursing
Description: Managing pain Cardiovascular stability Wound care Bowel function/Stoma Complications Education
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Peer Support Group
Description: Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative Peer Support Group
Description: Weekly sessions moderated by a social worker including patients and carers:~Safe space Share experiences/ideas Support Education
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
Study NCT06212700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants allocated to the control group will receive usual care according to their health care team, which may consist of advice on smoking cessation, reduction of alcohol intake, nutritional counselling, and medical optimisation in the preoperative anaesthetic clinic visits.
Study NCT05502315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40 mg taken orally
Study NCT05502315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg by infusion